I understand that a lot has been left on the table with the US...

I understand that a lot has been left on the table with the US market and a new HCC filing along with a US sales team could be game changing with a 3-5x sales increase.

Not sure if SRX have this at the moment.

yes very disappointing that Medtronic, Boston Scientific or J&J. I think Bayer would also be interested.

@cafa you might be on the money for the short term nature of the instos. I am thinking that Allan Grey are pushing for something and I suspect they are behind this latest media briefing as their quotes are front and centre in the article.

My thoughts was that the current board did a good job with the Bruce Grey mess but in the last 4 years a new board that has good knowledge in the space and has executive experience.

I own SRX but I also own OSL and Dr Chris Roberts and Dr Martin Cross are excellent experienced members. Have a look at their backgrounds. Where is that with the SRX board?

My gut is that PE might make a bid once they can lock down a manager to run SRX for this upside.

Let's hope it is north of $20 as a starting bid.